All News - Eli Lilly and Company
网页Lilly's latest press releases, stories, news resources and more.
Lilly.com | Eli Lilly and Company
网页INDIANAPOLIS , Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's …
Eli Lilly and Company (LLY) Latest Stock News & Headlines
网页Get the latest Eli Lilly and Company (LLY) stock news and headlines to help you in your trading and investing decisions.
News Release - Eli Lilly and Company
网页FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. May 13, 2022. PDF Version. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials.
News Release - Eli Lilly and Company
网页INDIANAPOLIS, April 17, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints.
Eli Lilly (LLY) earnings Q2 2024 - CNBC
网页2024年8月8日 · That compares with a profit of $1.76 billion, or $1.95 a share, a year earlier. Excluding one-time items associated with the value of intangible assets and other adjustments, Eli Lilly posted ...
News Release - Eli Lilly and Company
网页2023年11月8日 · Lilly is putting a commercial savings card program in place that will help people who may benefit from Zepbound better access it. People who are commercially insured with coverage for Zepbound may be eligible to pay as low as $25 for a 1-month or 3-month prescription.
Lilly hits record high after Mounjaro fuels forecast raise, rival data
网页2023年8月8日 · Eli Lilly on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares soaring 18% to a record...
Alzheimer's drug donanemab shows positive results, Eli Lilly ... - CNBC
网页2023年7月17日 · Eli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month.
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
网页6 天之前 · Eli Lilly and Company’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry.The stock has also outperformed the sector as well as the S&P 500 as seen in ...
跳至内容